Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2000, p. 3101-3106, Vol. 44, No. 11
Pneumococcal Diseases Research Unit, South
African Institute for Medical Research, University of the
Witwatersrand, and the Medical Research Council, Johannesburg, South
Africa,1 and Schering Plough
Research Institute, Kenilworth, New Jersey2
Received 5 June 2000/Returned for modification 25 July
2000/Accepted 21 August 2000
Spontaneous mutants of susceptible clinical and laboratory isolates
of Streptococcus pneumoniae exhibiting reduced
susceptibility to evernimicin (SCH27899; MIC, 0.5 to 4.0 mg/liter) were
selected on plates containing evernimicin. Four isolates that did not
harbor mutations in rplP (which encodes ribosomal protein
L16) were further analyzed. Whole chromosomal DNA or PCR products of
the 23S ribosomal DNA (rDNA) operons from these mutants could be used
to transform the susceptible S. pneumoniae strain R6 to
resistance at frequencies of 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Evernimicin (SCH27899) Inhibits a Novel Ribosome Target Site:
Analysis of 23S Ribosomal DNA Mutants
5 and 10
4,
respectively, rates 10- to 100-fold lower than that for a single-allele chromosomal marker. The transformants appeared slowly (48 to 72 h)
on selective medium, and primary transformants passaged on nonselective
medium produced single colonies that displayed heterogeneous susceptibilities to evernimicin. A single passage on selective medium
of colonies derived from a single primary transformant homogenized the
resistance phenotype. Sequence analysis of the 23S rDNA and rRNA from
the resistant mutants revealed single, unique mutations in each isolate
at the equivalent Escherichia coli positions 2469 (A
C), 2480 (C
T), 2535 (G
A), and 2536 (G
C). The mutations
map within two different stems of the peptidyltransferase region of
domain V. Because multiple copies of rDNA are present in the
chromosome, gene conversion between mutant and wild-type 23S rDNA
alleles may be necessary for stable resistance. Additionally, none of
the characterized mutants showed cross-resistance to any of a spectrum
of protein synthesis inhibitors, suggesting that the target site of
evernimicin may be unique.
*
Corresponding author. Present address: Laboratory of
Pediatrics, Erasmus University Rotterdam, Posbus 1738, 3000 DR
Rotterdam, The Netherlands. Phone: 31-10-4087951. Fax: 31-10-4089486. E-mail: adrian{at}kgk.fgg.eur.nl.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»